LIPOSOME COMPOSITION AND PHARMACEUTICAL COMPOSITION

    公开(公告)号:US20200016079A1

    公开(公告)日:2020-01-16

    申请号:US16583518

    申请日:2019-09-26

    Abstract: An object of the present invention is to provide a liposome composition and a pharmaceutical composition, which exhibit a high AUC. Provided are a liposome composition including a hydrophilic polymer-modified diacylphosphatidylethanolamine, a dihydrosphingomyelin, and cholesterols as components of a liposome membrane, in which the liposome composition encapsulates a drug, an inner water phase thereof contains ammonium sulfate, and a molar ratio of sulfate ions in the inner water phase to the drug in an entire water phase is 0.36 or more; and a pharmaceutical composition including the liposome composition.

    LIPID COMPOSITION
    5.
    发明公开
    LIPID COMPOSITION 审中-公开

    公开(公告)号:US20230210993A1

    公开(公告)日:2023-07-06

    申请号:US18182733

    申请日:2023-03-13

    CPC classification number: A61K47/18 A61K47/28 A61K47/24 A61K31/7088 A61K47/10

    Abstract: An object of the present invention is to provide a lipid composition capable of achieving excellent nucleic acid delivery. According to the present invention, there is provided a lipid composition containing a lipid represented by Formula (1) or a salt thereof, a nucleic acid, at least one non-cationic lipid, and a lipid represented by R51-L-(OCH2CH2)n—O-R52 (in the formula, R51 represents a hydrocarbon group having 6 to 30 carbon atoms, L represents —CO— or a single bond, R52 represents a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, and n represents an integer of 10 to 150).




    In the formula, each symbol means the definition described in the description.

    LIPOSOME COMPOSITION AND PHARMACEUTICAL COMPOSITION

    公开(公告)号:US20210038518A1

    公开(公告)日:2021-02-11

    申请号:US17079759

    申请日:2020-10-26

    Abstract: An object of the present invention is to provide a liposome composition and a pharmaceutical composition, which exhibit a high AUC. Provided are a liposome composition including a hydrophilic polymer-modified diacylphosphatidylethanolamine, a dihydrosphingomyelin, and cholesterols as components of a liposome membrane, in which the liposome composition encapsulates a drug, an inner water phase thereof contains ammonium sulfate, and a molar ratio of sulfate ions in the inner water phase to the drug in an entire water phase is 0.36 or more; and a pharmaceutical composition including the liposome composition.

    LIPOSOME AND LIPOSOME COMPOSITION
    7.
    发明申请

    公开(公告)号:US20180296485A1

    公开(公告)日:2018-10-18

    申请号:US16013355

    申请日:2018-06-20

    Abstract: An object of the present invention is to provide a liposome and a liposome composition in which release of a drug in blood is suppressed during accumulation of the liposome and the liposome composition in a target site such as a tumor and the drug is rapidly removed after the liposome and the liposome composition are sufficiently accumulated. According to the present invention, there is provided a liposome containing at least a phospholipid to which a hydrophilic polymer is bonded, a phospholipid having a negative charge within a range of a pH of 6 to 8, and a phospholipid which is electrically neutral within a range of a pH of 6 to 8, in which an average carbon chain length of the phospholipid to which the above-described hydrophilic polymer is bonded is shorter than an average carbon chain length of the above-described phospholipid which is electrically neutral within a range of a pH of 6 to 8.

Patent Agency Ranking